Farmasiselskapet Servier agomelatin 2003 og Mediator søksmål 2021

Agomelatine mot vinterdepresjon. Mediator slankemiddel. Begge fra det franske farmasiselskapet Servier.

I 2003 deltok jeg i utprøving av et middel mot lett vinterdepresjon. Medisinen ble laget av det franske legemiddelfirmaet Servier. Utprøvingen gikk over ett års tid her i Oslo. Jeg hadde jevnlig kontakt med en lege/psykolog. Når dette skrives, 18. februar 2022, vet jeg fortsatt ikke om jeg fikk legemiddelet eller placebo.

Nå er samme firma Servier i en stor rettssak over slankemiddelet Mediator. Middelet har tatt livet av tusenvis av mennesker.

Agomelatin 2003-2004

Wikipedia Agomelatine is used for the treatment of major depressive episodes in adults in Europe. Ten placebo controlled trials have been performed to investigate the short term efficacy of agomelatine in major depressive disorder. At the end of treatment, significant efficacy was demonstrated in six of the ten short-term double-blind placebo-controlled studies. Two were considered “failed” trials, as comparators of established efficacy failed to differentiate from placebo. Efficacy was also observed in more severely depressed patients in all positive placebo-controlled studies. The maintenance of antidepressant efficacy was demonstrated in a relapse prevention study. One meta-analysis found agomelatine to be as effective as standard antidepressants.

Jeg brukte middelet omtrent 1 års tid. I forkant hadde jeg hatt en periode på litt over ett år der jeg følte meg lett depressiv. Da jeg gikk på middelet følte jeg det hjalp noe. Jeg hadde ingen bivirkninger.

Email til Servier desember 2021 og januar-februar 2022.

Hi, thank you very much for our phone conversation. I am a norwegian man living in the Oslo area. I participated in a Servier clinical trial in the years 2003-2004 here in Norway. My contact was doctor/psychiatrist Andres Magnusson. He is originally from Iceland. The study was for winterdepression, with the drug S-20098 agomelatin. Attached is the agreement that I signed. (it is in Norwegian). I would like to know the results from the study. I would also like all information collected about my participation. If I got the drug or placebo. The study protocol – how much and how often I took the drug. Startdate and enddate. The questionnaires and assessments from my regular meetings with Dr. Magnusson. And all other information available. All information can be sent to me to this email. I can be reached through this email or my homephone +47 (—). Kind regards,

Antidepressant efficacy of agomelatine meta-analysis of published and unpublished studies.


Wikipedia. Benfluorex, sold under the brand name Mediator, is an anorectic and hypolipidemic agent that is structurally related to fenfluramine (a substituted amphetamine). It may improve glycemic control and decrease insulin resistance in people with poorly controlled type-2 diabetes. It was on the market between 1976 and 2009, and is thought to have caused between 500 and 2,000 deaths. It was patented and manufactured by the French pharmaceutical company Servier. However, Servier is suspected of having marketed benfluorex at odds with the drugs medical properties. On March 29, 2021, a French court fined Servier euro 2.7 millions after finding it guilty of deception and manslaughter.

BBC. Published 29 March 2021. Mediator drug: French pharmaceutical firm fined over weight loss pill. The drug Mediator was developed for use in overweight diabetics and was on the market for 33 years. It was eventually withdrawn in 2009 over concerns it could cause serious heart problems. 2. august 2019. Who in France does not have something to say about the Mediator affair? It is a subject which has elicited a very emotional response, and is a very complex and unusual case. But this does not excuse the irrelevancies, the inaccuracies, and even false and libellous statements, which have appeared and have been repeated in the media.